Superficial Cutaneous Infections and Pyodermas
Superficial cutaneous infections and pyodermas are a common group of bacterial skin infections confined to the epidermis and the upper dermis or hair follicles. The two leading culprits are Staphylococcus aureus and group A streptococcus (Streptococcus pyogenes, GAS). They range from superficial epidermal infections such as impetigo and ecthyma to folliculitis, furuncles (boils) and carbuncles, and on to deeper involvement of hair follicles and sweat glands. Skin damage comes not only from bacterial multiplication but also from toxins (enterotoxins, exfoliative toxins A and B) and extracellular enzymes released by the bacteria. Rising antibiotic resistance, particularly methicillin-resistant S. aureus (MRSA), makes treatment increasingly challenging. At Haute-Derma, we combine microbiologic diagnosis (direct microscopy with Gram stain, culture and susceptibility testing) with targeted antibiotic treatment and thorough care of the skin barrier.
How these infections develop in the skin and how the immune system responds:
- Surface invasion and bacterial adhesion:
- S. aureus and S. pyogenes use surface proteins (such as protein A and fibronectin-binding proteins) to attach to keratinocytes wherever the skin barrier is broken, for example by scratches, insect bites or atopic dermatitis.
- They release lipase and hyaluronidase, which break down barrier lipids and hyaluronic acid in the tissue spaces, clearing a path for the infection to spread.
- Exfoliative toxins A/B and blister or pustule formation:
- In bullous impetigo, exfoliative toxins A (ETA) and B (ETB) produced by S. aureus act as proteases that specifically cleave desmoglein 1, an adhesion protein, in the granular layer of the epidermis.
- Loss of this adhesion separates keratinocytes in the upper epidermis (acantholysis), producing thin, superficial blisters that break easily and leave moist, weeping erosions.
- Neutrophil-driven inflammation and pus formation:
- Bacterial peptidoglycan and teichoic acid activate TLR2 receptors on immune cells, triggering release of proinflammatory cytokines such as IL-1beta, TNF-alpha and IL-8.
- The surge of IL-8 draws large numbers of neutrophils into the infected area. As they engulf bacteria and release reactive oxygen species (ROS) and elastase, keratinocytes die; together with degenerating white cells, this debris forms the pus typical of pyoderma.
Clinical Features of Superficial Infections and Pyodermas
| Condition | Typical Clinical Features | Main Organism |
|---|---|---|
| Non-bullous impetigo | Superficial vesicles or pustules that rupture quickly and form honey-colored crusts. | S. aureus alone or together with S. pyogenes. |
| Bullous impetigo | Flaccid blisters whose clear fluid turns cloudy; they rupture to leave red erosions with a collarette of scale. | S. aureus (producing ETA/ETB toxins). |
| Superficial folliculitis | Small pustules the size of a pea centered on a hair follicle, with a red halo; mildly itchy or tender. | S. aureus; Pseudomonas aeruginosa (hot tub/pool folliculitis). |
| Furuncle and carbuncle | A red, firm, very painful swelling that later softens with pus at the center (furuncle). Several furuncles merge into a larger plaque with multiple draining openings (carbuncle). | S. aureus (especially PVL toxin–producing strains). |
| Ecthyma | Round, shallow ulcer with a raised, punched-out edge, covered by a thick gray-black crust; removing the crust reveals a painful ulcer. | S. pyogenes (group A streptococcus). |
Bullous Impetigo vs. Pemphigus Foliaceus vs. Infected Atopic Dermatitis
| Bullous Impetigo | Pemphigus Foliaceus | Infected Atopic Dermatitis (AD) |
|---|---|---|
| Bacterial infection from an external source | Autoimmune disease targeting desmoglein 1 | Chronic dermatitis with secondary bacterial infection |
| Superficial honey-colored crusts | Dry, thin, flaky crusts | Rough, eroded skin with purulent crusting |
| Superficial blisters containing pus that collapse quickly | Very superficial blisters, rarely seen intact | Weeping and tiny papules; no large blisters |
| Many Gram-positive cocci | No bacteria (unless secondarily infected) | Gram-positive cocci colonizing a wide area |
| Topical / systemic antibiotics | Systemic corticosteroids, immunosuppressants | Antibiotics plus moisturizers and mild corticosteroids |
Our Approach
At Haute-Derma, we manage superficial skin infections and pyodermas according to sound microbiology principles, so treatment works and resistance is avoided:
- Gram stain and direct microscopy: Pus or fluid from beneath the crust is Gram-stained to quickly show whether Gram-positive cocci are arranged in chains (Streptococcus) or clusters (Staphylococcus).
- Bacterial culture and susceptibility testing: Required for recurrent infections, failure of initial treatment or suspected methicillin-resistant S. aureus (MRSA).
- Risk factor and barrier function assessment: We check for persistent nasal carriage of staphylococci and look for breakdown of the stratum corneum caused by underlying skin conditions (atopic dermatitis, scabies, insect bites).
Treatments at Haute-Derma
Our protocol focuses on controlling infection locally, avoiding unnecessary systemic antibiotics and restoring the skin barrier:
- Evidence-based topical and systemic antibiotics:
- Topical antibiotics: mupirocin 2% or fusidic acid 2%, applied 2–3 times a day for 5–7 days, for localized impetigo or superficial folliculitis.
- Systemic antibiotics: used for widespread lesions, systemic symptoms (fever) or carbuncles. Preferred options are cephalexin, cloxacillin, or clindamycin/trimethoprim-sulfamethoxazole (if MRSA is suspected).
- Wound cleansing and care:
- Soaking or washing the affected skin with chlorhexidine 4% or hypochlorous acid (HOCl) softens honey-colored crusts so they can be lifted off gently without injuring the skin.
- Absorbent antimicrobial dressings help clear pus that collects in ruptured boils.
- Staph decolonization and barrier repair to prevent recurrence:
- Clearing nasal carriage: for recurrent boils, mupirocin 2% is applied inside both front nostrils twice a day for 5 days each month.
- Restoring skin lipids: a repair moisturizer containing ceramides and licochalcone A, started once the acute infection is fully under control.
